Floatz logo

Carboplatin

Recurrent Squamous Cell Carcinoma of the Nasopharynx

Rapa Therapeutics LLCSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Squamous Cell Carcinoma of the Nasopharynx cohort.

Asset / SponsorPhaseRating
Cetuximab
National Cancer Institute (NCI)
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
AUTOLOGOUS RAPAMYCIN-RESISTANT TH1/TC1 CELLS RAPA-201
Rapa Therapeutics LLC
Phase 1/2CCC
Pembrolizumab
Rapa Therapeutics LLC
Phase 1/2CCC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 1CC

View all 15 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →